Clinical trial · no report yet · Phase 3
NCT03811002
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)
- NCT03811002 ↗
- Active not recruiting
- National Cancer Institute (NCI)
- 56 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 24 | |
| Podcasts | 20 | |
| YouTube | 12 |
The trial
ClinicalTrials.gov- Official title
- Limited Stage Small Cell Lung Cancer (LS-SCLC): A Phase III Randomized Study of Chemoradiation Versus Chemoradiation Plus Atezolizumab
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Limited Stage Lung Small Cell Carcinoma; Stage I Lung Cancer AJCC v8; Stage II Lung Cancer AJCC v8; Stage III Lung Cancer AJCC v8
- Interventions
- 3-Dimensional Conformal Radiation Therapy; Atezolizumab; Biospecimen Collection; Carboplatin; Cisplatin; Etoposide; Intensity-Modulated Radiation Therapy; Quality-of-Life Assessment; Questionnaire Administration
- Arms
- Arm I (chemotherapy, radiation therapy) · Active comparator
- Arm II (chemotherapy, radiation therapy, atezolizumab) · Experimental
- Enrollment
- 544
- Primary outcomes
- Overall Survival
- Sponsor
- National Cancer Institute (NCI) with NRG Oncology
- Start
- Jul 26, 2019
- Primary completion
- Apr 21, 2024
- Results posted
- Yes
- Registry record
- NCT03811002 · updated Aug 27, 2026
Publications
linked from the registry- Movsas B, Hu C, Higgins KA, Ross HJ, Jabbour SK, Kozono D, Owonikoko TK, Xiao C, Shoji T, Faller BA, Mohindra P, Dib EG, Brownstein J, Chun SG, Kuzma CS, Kotecha R, Onitilo A, Mulford D, Paulus R, Bradley JD, Bruner DW. Comprehensive Patient-Reported Outcomes from NRG Oncology/Alliance LU005: A Randomized Trial of Chemoradiation With or Without Atezolizumab in Limited-Stage SCLC. J Thorac Oncol. 2026 Jul 30:104117. doi: 10.1016/j.jtho.2026.104117. Online ahead of print. PubMed 42532339
- Higgins KA, Hu C, Ross HJ, Jabbour SK, Kozono DE, Owonikoko TK, Ritter TA, Williams TM, Welsh J, Simko JP, Movsas B, Xiao C, Kaira K, Gupta AK, Mohindra P, Dib EG, Brownstein J, Chun S, Kuzma CS, Kotecha R, Onitilo AA, Chen Y, Stinchcombe TE, Wang X, Paulus R, Bradley JD. Chemoradiation +/- Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. J Clin Oncol. 2026 Mar 10;44(8):630-640. doi: 10.1200/JCO-25-01569. Epub 2026 Jan 13. PubMed 41529214
- Higgins KA, Thomas A, Soto N, Paulus R, George TJ, Julian TB, Hartson Stine S, Markham MJ, Werner-Wasik M. Creating and Implementing a Principal Investigator Tool Kit for Enhancing Accrual to Late Phase Clinical Trials: Development and Usability Study. JMIR Cancer. 2022 Aug 25;8(3):e38514. doi: 10.2196/38514. PubMed 36006678